Proceedings of the National Academy of Sciences · 2009 · 114 citations · 46 references
Life SciencesNeurosciencePharmacologyDrug DiscoveryMolecular NeuroscienceNeuropharmacologyAlzheimer DiseaseChannel StructureMolecular Basis Of NeurodegenerationNeurodegenerative DiseasesNeurodegenerative DisordersNeuroprotectionAlzheimer Disease NeuroprotectionAmyloid Beta AggregationAmyloid Beta PeptidesCalcium Channel FunctionCalcium Channel ModulatorsCalcium Channel PharmacologyNeurodegenerative Disease MechanismsNeurotoxic Action
Alzheimer's disease (AD) is a common, chronic neurodegenerative disease that is thought to be caused by the neurotoxic effect of the Amyloid beta peptides (Abeta). We have hypothesized that the intrinsic Abeta calcium channel activity of the oligomeric Abeta polymer may be responsible for the neurotoxic properties of Abeta, and that Abeta channel blockers may be candidate AD therapeutics. As a consequence of a rational search paradigm based on the model structure of the Abeta channel, we have identified two compounds of interest: MRS2481 and an enatiomeric species, MRS2485. These are amphiphilic pyridinium salts that both potently block the Abeta channel and protect neurons from Abeta toxicity. Both block the Abeta channel with similar potency (approximately 500 nM) and efficacy (100%). However, we find that inhibition by MRS2481 is easily reversible, whereas inhibition by MRS2485 is virtually irreversible. We suggest that both species deserve consideration as candidates for Alzheimer's disease drug discovery.
46
The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
Jie Kang, Hans-Georg Lemaire, Axel Unterbeck et al. · Nature · 1987 · 4.6K citations
Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse
Dale Schenk, Robin Barbour, Whitney Dunn et al. · Nature · 1999 · 3.2K citations